Click here to receive MS news via e-mail
Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing multiple sclerosis treatment.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the European Commission approve the tablets.
“The positive opinion from the CHMP [the committee] is an extraordinary development for our company, affirming our belief in cladribine tablets as a potential important treatment option for patients living with multiple sclerosis,” Belén Garijo, a Merck board member, said in a press release.
“We now eagerly await the European Commission decision, and the opportunity to make a difference in the MS treatment paradigm,” he said. “Our sincerest thanks to the entire MS community for their unwavering support throughout the cladribine tablets journey.”
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
MS Views and News provides beneficial information for those affected by Multiple Sclerosis.
Join us by registering here: www.register.msviewsandnews.org